|
Disis, Mary L; Goodell, Vivian; Schiffman, Kathy et al. (2004) Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J Clin Immunol 24:571-8
|
|
Disis, Mary L; Shiota, Faith M; McNeel, Douglas G et al. (2003) Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens. Immunobiology 207:179-86
|
|
Disis, Mary L; Gooley, Theodore A; Rinn, Kristine et al. (2002) Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20:2624-32
|
|
Schiffman, Kathy; Rinn, Kristine; Disis, Mary L (2002) Delayed type hypersensitivity response to recall antigens does not accurately reflect immune competence in advanced stage breast cancer patients. Breast Cancer Res Treat 74:17-23
|
|
Disis, Mary L; Rinn, Kristine; Knutson, Keith L et al. (2002) Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood 99:2845-50
|
|
Disis, M L; Schiffman, K (2001) Cancer vaccines targeting the HER2/neu oncogenic protein. Semin Oncol 28:12-20
|
|
Disis, M L; Knutson, K L; Schiffman, K et al. (2000) Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat 62:245-52
|
|
McNeel, D G; Disis, M L (2000) Tumor vaccines for the management of prostate cancer. Arch Immunol Ther Exp (Warsz) 48:85-93
|
|
McNeel, D G; Nguyen, L D; Storer, B E et al. (2000) Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer. J Urol 164:1825-9
|
|
Disis, M L; Schiffman, K; Gooley, T A et al. (2000) Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin Cancer Res 6:1347-50
|
Showing the most recent 10 out of 20 publications
